Patricia Lawman, PhD, co-founder and CEO of Morphogenesis, Inc. since 2003, received her graduate education in molecular biology and immunology from the College of Medicine at the University of Florida where she also served as a Postdoctoral Fellow in Pediatric Hematology and Oncology. Prior to founding Morphogenesis, Dr. Lawman was Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute. She has held adjunct faculty positions at the University of Central Florida and the University of South Florida and has served on numerous committees at local/state/federal levels. Dr. Lawman holds over 30 patents and as many publications and has received multiple business and scientific honors. Morphogenesis is an emerging clinical stage cell and gene therapy company. The company is testing its off-the-shelf, personalized cancer immunotherapy in two ongoing human clinical trials with a Phase II skin cancer basket trial planned for 2020.